Tha FDA granted Aimmune Nestle orphan status for its treatment of fatty acid oxidation disorders, D-beta-hydroxybutyrate.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NSRGY:
- European Stocks: Unnoticed Records, Overlooked Opportunities
- Nestle price target lowered to CHF 116 from CHF 122 at Berenberg
- Nestle upgraded to Sector Perform from Underperform at RBC Capital
- Nestle price target lowered to CHF 110 from CHF 125 at Barclays
- Nestle downgraded to Hold from Buy at Stifel
